neobookRx
GuidelinesOther guideline

References

These are the approved guidelines published by the South African Society of Psychiatrists to provide an overview on treatment and management of commonly diagnosed psychiatric illnesses. The guidelines include consensus recommendations, based on peer contribution and using the international evidence based guidelines that are suitable for the local South African health service.

Please note that parts of this guideline may be out of date, an update will be published as soon as it is available.

  1. Wimo A, Prince M. World Alzheimer Report 2010. London: Alzheimer’s Disease International, 2010.
  2. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: A quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-479.
  3. Cummings JL, Jeste DV. Alzheimer’s disease and its management in the year 2010. Psychiatr Serv 1999;50:1173-1177.
  4. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 2000;54(11 Suppl 5):S4-9.
  5. Breitner JCS, Haneuse SJPA, Walker R, et al. Risk of dementia and Alzheimer’s disease with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009;72:1899-1905.
  6. Kester MI, Scheltens P. Dementia: the bare essentials. Practical Neurology 2009;9:241-251.
  7. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management and risk factors. Lancet Neurology 2008;7:812-826. [http://dx.doi.org/10.1016/S1474-4422(08)70169-8]
  8. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimer’s and Dementia 2010;6:98-103. [http://dx.doi.org/10.1016/j.jalz.2010.01.010]
  9. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s and Dementia 2007;3:186-191. [http://dx.doi.org/10.1016/j.jalz.2007.04.381]
  10. Potocnik F. Psychogeriatrics. In: Emsley RA, Pienaar WP, eds. Textbook of Psychiatry, EDS. Tygerberg, Cape Town: Mental Health Information Centre of South Africa, 2005: 81-101.
  11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders,Fourth Edition, Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000.
  12. Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
  13. Cummings JL. The Neuropsychiatry of Alzheimer’s Disease and Related Dementias. London: Martin Dunitz, 2003.
  14. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s disease cooperative study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-39.
  15. Feldman HH, van Baelen B, Kavanagh SM, Torfs KE. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: A 12-month analysis. Alzheimer Dis Assoc Disord 2005;19:29-36.
  16. Potocnik F, Pienaar W. The elderly. In: Kaliski S, ed. Psycholegal Assessment in South Africa.Cape Town: Oxford University Press, 2006:271-286.
  17. Hort J, O’Brien JT, Gainotti G, et al. on behalf of the European Federation of the Neurological Societies (EFNS) Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17:1236-1248. [http://dx.doi.org/10.1111/j.1468-1331.2010.03040.x]
  18. Gauthier S, Cummings J, Ballard C, et al. Management of behavioural problems in Alzheimer’sdisease. Int Psychogeriatr 2010;22:346-372. [http://dx.doi.org/10.1017/S1041610209991505]
  19. Ames D, Cheu E, Lindesay J, Shulman KI. Guide to the Psychiatry of Old Age. Cambridge: Cambridge University Press, 2010:31-47.
  20. Taylor D, Paton C, Kapur S. Maudsley Prescribing Guidelines, 10th ed. London: InformaHealthcare, 2009: 388-399.
  21. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80:600-607. [http://dx.doi.org/10.1136/jnnp.2008.158964]
  22. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects ofcerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paperfrom the Alzheimer’s Biomarkers Standardization Initiative. Alzheimer’s and Dementia2012;8:65-73. [http://dx.doi.org/10.1016/j.jalz.2011.07.004]
  23. Rogers SL, Doody RS, Pratt RD, Jeni JR. Long-term efficacy and safety of donepezilin the treatment of Alzheimer’s disease: Final analysis of a US multicentre open-labelstudy. Eur Neuropsychopharmacol 2000;10:195-203. [http://dx.doi.org/10.1016/S0924-977X(00)00067-5]
  24. Winblad B, Wimo A, Engedal K, et al. for the Donepezil Nordic Study Group. 3-year study of donepezil therapy in Alzheimer’s disease: Effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006;21:353-363. [http://dx.doi.org/10.1159/000091790]
  25. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. New Engl J Med 2012;366:893-903. [http://dx.doi.org/10.1056/NEJMoa1106668]
  26. Hogan DB. Progress update: Pharmacological treatment of Alzheimer’s disease. Neuropsychiatric Disease and Treatment 2007;3:569-578.
  27. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: Effects onnursing home placement and mortality. Neurology 1996;47:166-177.
  28. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer’s disease. Clin Ther 1997;19:330-345.
  29. Stewart A, Phillips R, Dempsey G. Pharmaco therapy for people with Alzheimer’s disease: AMarkov-cycle evaluation of five years’ therapy using donepezil. Int J Geriatr Psychiatry 1998;13:445-453.[http://dx.doi.org/10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.3.CO;2-5]
  30. Doody RS, Geldmacher DS, Gordon B, et al. Open label, multicenter, phase 3 extension study of the safely and efficacy of donepezil in patients with Alzheimer’s disease. Arch Neurol 2001;58:427-433.
  31. National Institute for Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. Technology Appraisal No111. http://www.nice.org.uk.2006 (accessed April 2013).
  32. Taylor D, Paton C, Kapur S. Behavioural and Psychological Symptoms of Dementia. Maudsley Prescribing Guidelines, 10th edition. London: Informa Healthcare, 2009:400-404.
  33. Ihl R, Frölich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World Journal of Biological Psychiatry 2011;12:2-32. [http://dx.doi.org/10.3109/15622975.2010.538083]
  34. Rossiter D, ed. South African Medicines Formulary (SAMF), 10th ed. Cape Town: Health and Medical Publishing Group of the South African Medical Association, 2012.
  35. Cummings JL, Mega MS, Gray K, et al. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2380-2314.
  36. Ames D, Cheu E, Lindesay J, Shulman KI. Guide to the Psychiatry of Old Age. Cambridge, UK:Cambridge University Press, 2010:49-56.
  37. Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: The aging, demographics, and memory study. J Am Geriatr Soc 2010;25:330-337. http://dx.doi.org/10.1111/j.1532-5415.2009.02680.x
  38. Potocnik F. Forgetfulness and other disturbances of cognitive function: The dementias. In: Baumann SE, ed. Primary Health Care Psychiatry. A Practical Guide for Southern Africa. CapeTown: Juta, 2007:494-508.
  39. Potocnik F. Successful treatment of hypersexuality in AIDS dementia with cyproteroneacetate. S Afr Med J 1992;81:433-435.
  40. Jones DA, Peters TJ. Caring for the elderly dependents: Effects on the carer’s quality of life. Age Ageing 1992;21:421-428.
  41. Eisdorfer C. Families in distress: Caring is more than loving. Psychiatr Ann 1996;26:285-288.42. Norton MC, Smith KR, Ostbye T, et al. for the Cache County Investigators. Greater risk ofdementia when spouse has dementia? The Cache County study. J Am Geriatr Soc 2010;58:895-900. [http://dx.doi.org/10.1111/j.1532-5415.2010.02806.x]
  42. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 2006;314:777-781.[http://dx.doi.org/10.1126/science.1132814]
  43. Breteler MMB, Hofman A, Launer LJ, et al. Pharmacologic agents associated with a preventive effect on Alzheimer’s disease: A review of the epidemiologic evidence. Epidemiol Rev2002;24:248-268.151 SAJP - August 2013 Vol. 19 No. 3
  44. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer’s disease in users ofanti-oxidant vitamin supplements: The cache county study. Arch Neurol 2004;61:82-88.
  45. Miller ER, Pastor-Barriuso R, Dalai D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46. [http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00110]
  46. Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: A prospective community study in the Bodeaux area. Revue Neurologique. (Paris) 1997;153:185-192.
  47. t’Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer’s disease. New Engl J Med 2001;345:1515-1521.
  48. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimer’s & Dementia 2011;7:402-411.[http://dx.doi.org/10.1016/j.jalz.2010.12.014]
  49. Van Gelder BM, Buijsse B, Tijhuis M, et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: The FINE study. Eur J Clin Nutr 2007;61:226-232.[http://dx.doi.org/10.1038/sj.ejcn.1602495]
  50. Eskelinen MH, Ngandu T, Tuomilehto J, et al. Midlife coffee and tea drinking and the risk of late-life dementia: A population-based CAIDE study. Journal of Alzheimer’s Disease 2009;16:85-91.
  51. Cao C, Wang L, Lin X, et al. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer’s mice. Journal of Alzheimer’s Disease2011;25:323-335.
  52. Vellas B, Gillette-Guzonnet S, Andries S. Memory health clinics - a first step to prevention. Alzheimer’s & Dementia 2008;4 (Suppl 1):S144-149. [http://dx.doi.org/10.1016/j.jalz.2007.11.001]54. 
  53. Bowman GL, Silbert LC, Howieson D, et al. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 2012;78:241-249.55. 
  54. Daoud JB. Memory loss. Update 1998:40-45.

Drugs mentioned

NeoHealth® ID 20699 · updated 4/19/2022